Open AccessShould FOLFOXIRI Plus Bevacizumab Be the Standard First‐Line Therapy in Metastatic Colorectal Cancer?
Author(s) -
Nipp Ryan D.,
Ryan David P.
Publication year - 2015
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2014-0495
Subject(s) - medicine , bevacizumab , folfiri , colorectal cancer , regimen , oncology , irinotecan , chemotherapy , cancer
The TRIBE trial compared the FOLFOXIRI regimen plus bevacizumab with FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. FOLFOXIRI plus bevacizumab is an acceptable therapeutic option, but the results of the TRIBE trial do not establish this regimen as the best treatment option for patients with metastatic colorectal cancer.